-
1دورية
المصدر: Drug Week; 7/5/2024, p310-310, 1p
مصطلحات موضوعية: SODIUM-glucose cotransporters, GLUCAGON-like peptide-1 receptor, SODIUM-glucose cotransporter 2 inhibitors, HEART failure, GLUCAGON-like peptide-1 agonists, COGNITION disorders
مصطلحات جغرافية: CAMPANIA (Italy)
-
2دورية
المصدر: Cancer Weekly; 6/25/2024, p958-958, 1p
مصطلحات موضوعية: SODIUM-glucose cotransporter 2 inhibitors, CARDIOMYOPATHIES, CANCER treatment, DAPAGLIFLOZIN, VENTRICULAR ejection fraction, RESEARCH institutes
-
3دورية
المصدر: Drug Week; 6/21/2024, p1109-1109, 1p
مصطلحات موضوعية: HEART failure, CANAGLIFLOZIN, SODIUM-glucose cotransporter 2 inhibitors
-
4دورية
المصدر: Cardiovascular Week; 6/17/2024, p592-592, 1p
مصطلحات موضوعية: HEART failure, SODIUM-glucose cotransporter 2 inhibitors, TYPE 2 diabetes, RESEARCH personnel, STATE universities & colleges, CONTROLLED substances
الشركة/الكيان: RUTGERS University (Newark, N.J.)
-
5دورية
المصدر: Cardiovascular Week; 6/17/2024, p594-594, 1p
مصطلحات موضوعية: HEART failure, EMPAGLIFLOZIN, SODIUM-glucose cotransporter 2 inhibitors, RESEARCH personnel
-
6دورية
المصدر: Cardiovascular Week; 6/17/2024, p965-965, 1p
مصطلحات موضوعية: HEART failure, HEART failure patients, SODIUM-glucose cotransporter 2 inhibitors, RESEARCH personnel, TREATMENT effectiveness
-
7دورية
المصدر: Diabetes Week; 6/11/2024, p1314-1314, 1p
مصطلحات موضوعية: EMPAGLIFLOZIN, HEART failure, OLDER patients, UNIVERSITY hospitals, SODIUM-glucose cotransporter 2 inhibitors, OBESITY
-
8دورية
المصدر: Heart Disease Weekly; 6/10/2024, p274-274, 1p
مصطلحات موضوعية: TACHYARRHYTHMIAS, HEART failure, ATRIAL fibrillation, CATHETER ablation, DAPAGLIFLOZIN, ATRIAL flutter, SODIUM-glucose cotransporter 2 inhibitors
-
9دورية
المصدر: Clinical Trials Week; 6/3/2024, p299-299, 1p
مصطلحات موضوعية: HEART failure patients, SODIUM-glucose cotransporter 2 inhibitors, HEART failure, VENTRICULAR ejection fraction, URINARY tract infections, PHARMACEUTICAL policy, COHORT analysis
-
10دورية
المصدر: Diabetes Week; 6/3/2024, p221-221, 1p
مصطلحات موضوعية: HEART failure, DIABETES, EMPAGLIFLOZIN, SODIUM-glucose cotransporter 2 inhibitors, DAPAGLIFLOZIN, PEOPLE with diabetes